Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
Every story we pull is tagged to the disease it’s about — so you can filter to your condition and read only what matters.
Showing news related to
selpercatinib improves efs in ret fusion positive nsclc
Original title: “Selpercatinib Improves EFS in RET Fusion-Positive NSCLC.”
Analysts, investors and partner Summit Therapeutics had all been keenly awaiting the overall survival update, after previous data from Akeso’s HARMONi-6 trial left them wanting.
Original title: “ASCO: Akeso’s VEGF/PD-1 boosts lung cancer survival, relieving pressure on US partner Summit”
Ivonescimab reduced the risk of death by one-third compared to chemotherapy in a China-based study that’s seen as an important barometer for a class of cancer immunotherapies known as "PD-1/VEGF inhibitors."
Original title: “Akeso, Summit drug extends survival in closely watched lung cancer trial”
Treatment with the TROP2 ADC sac-TMT led to a 70% objective response rate and progression-free survival was “significantly improved” as compared to placebo—the second positive readout for the asset this week.
Original title: “Kelun-Merck validate TROP2-Keytruda pairing in lung cancer with improved survival”
hepatoid adenocarcinoma of the lung clinicopathologic and molecular analysis of 17 cases
Original title: “Hepatoid adenocarcinoma of the lung: clinicopathologic and molecular analysis of 17 cases.”
David Ross: Continuing Advocacy for Rare Diseases Two Decades After Losing a Loved One / cancer, David Ross, IPF, Karen Yada Ross, Lung cancer, Natera, Karen continues to advocate for rare diseases such as PH-ILD with a sense of dedication, humility, and compassion. As part of the Pulmovant team, she aspires to make a meaningful difference for these courageous patients.”
Original title: “David Ross: Continuing Advocacy for Rare Diseases Two Decades After Losing a Loved One - OncoDaily”
primary hepatoid adenocarcinoma of the lung with signet ring cell differentiation and widespread osseous metastases a case report
Original title: “Primary Hepatoid Adenocarcinoma of the Lung With Signet Ring Cell Differentiation and Widespread Osseous Metastases: A Case Report.”
declining incidence of large cell lung carcinoma in the united states effects of who reclassification in a seer analysis
Original title: “Declining Incidence of Large Cell Lung Carcinoma in the United States: Effects of WHO Reclassification in a SEER Analysis.”
radiotherapy based multimodal treatment in advanced nsclc with spinal infiltration a case series of seven unfavorable patients
Original title: “Radiotherapy-based multimodal treatment in advanced NSCLC with spinal infiltration: a case series of seven unfavorable patients.”
gastroparesis following anatomical resection for lung cancer clinical characteristics and implications
Original title: “Gastroparesis following anatomical resection for lung cancer: clinical characteristics and implications.”
As a result, targeted radionuclide ... of new treatment approaches, tailored to the nature and biology of different tumors. Later this year, a UK-based biotech company called Nuclide Therapeutics, is planning a clinical trial in lung cancer patients, a population with notoriously low overall survival rates. “The symptoms don’t often show until the disease has spread, ... As a result, targeted radionuclide therapy is set to become ever more varied and sophisticated in the coming years and could ultimately lead to a broad array of new treatment approaches, tailored to the nature and biology of different tumors. Later this year, a UK-based biotech company called Nuclide Therapeutics, is planning a clinical trial in lung cancer patients, a population with notoriously low overall survival rates. “The symptoms don’t often show until the disease has spread, making surgery difficult, and the cancer develops therapy resistance at a rapid rate,” says Tim Witney, professor of molecular imaging at King’s College London, and the company’s co-founder & CSO. Breakthroughs in identifying tumor biomarkers in liver, gastric, prostate, lung and other cancers and are accelerating radionuclide therapies. After being approved by the FDA in early 2022, it has emerged as a novel life-extending option for patients with advanced disease. ... The success of this drug has resulted in PSMA becoming a focal point for other radionuclide therapies aimed at advanced prostate cancer. Bayer has two early-stage clinical trials in progress using PSMA to deliver higher energy radionuclides to patients with metastatic disease. But once there’s data that shows, ‘Ok, this is safe and also as effective as standard treatments,’ then radiopharmaceuticals could be moved up as a first-line option where it’s the patient’s and physician’s choice about which treatment they want to receive.” · I look forward to watching these clinical trials carefully over the coming years—and one day, hopefully, welcoming a new standard tool into our toolbox for treating cancer.
Original title: “Precision Radiation Therapy Could Offer New Hope For Hard-To-Treat Cancers”
neuropsychiatric adverse events associated with lorlatinib in alk positive nsclc
Original title: “Neuropsychiatric adverse events associated with lorlatinib in ALK-positive NSCLC.”
patient with novel ppp1cb alk fusion advanced nsclc achieved long survival from alectinib a case report
Original title: “A Patient With Novel PPP1CB -ALK Fusion Advanced NSCLC Achieved Long Survival From Alectinib: A Case Report.”
entrectinib induced sinus bradycardia in a patient with metastatic non small cell lung cancer
Original title: “Entrectinib-Induced Sinus Bradycardia in a Patient With Metastatic Non-Small Cell Lung Cancer.”
carcinomas and carcinoid tumors of the lungs and bronchi in children and adolescents the expert recommendations
Original title: “Carcinomas and Carcinoid Tumors of the Lungs and Bronchi in Children and Adolescents: The EXPeRT Recommendations.”
placental transmogrification of the lung misdiagnosed as cavitary lung cancer a case report
Original title: “[Placental transmogrification of the lung misdiagnosed as cavitary lung cancer: a case report].”
increased detection of nrg1 fusions in non squamous non small cell lung cancer using combined dna and rna sequencing in a real world cohort
Original title: “Increased detection of NRG1 fusions in non-squamous non-small cell lung cancer using combined DNA and RNA sequencing in a real-world cohort.”
Incyte is looking to expand the use of its PD-1 blocker Zynyz to treat non-small cell lung cancer. The FDA’s rejection did not flag problems with the drug’s efficacy or safety.
Original title: “Incyte’s Lung Cancer Expansion Bid Thwarted by Issues at Novo’s Catalent-Acquired Site”
Hernexeos is the second drug to secure an FDA approval under the agency’s priority voucher scheme, following in the footsteps of USAntibiotics’ Augmentin XR, which was granted the ticket in December 2025.
Original title: “Boehringer Wins Speedy Lung Cancer Approval Under Commissioner’s Priority Program”
The U.S. Food and Drug Administration today issued an approval for the lung cancer drug Hernexeos (zongertinib) as a part of the new Commissioner's National Priority Voucher (CNPV) pilot program.
Original title: “FDA Grants Second Approval under the National Priority Voucher Pilot Program”